Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 13/20 | 0.65 |
| ▸ | NR1H3 | Q13133 | 13/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.44 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1272139 | 0.83 | NR1H2 (0.67) | NR1H2NR1H3CYP1A2THRBSMN1; SMN2 | |
| SCHEMBL1271081 | 0.82 | NR1H2 (0.57) | NR1H2NR1H3HTTPIK3R2 | |
| SCHEMBL1271040 | 0.81 | NR1H2 (0.67) | NR1H2NR1H3CYP1A2THRBSMN1; SMN2 | |
| SCHEMBL12934187 | 0.80 | THRB (0.48) | NR1H2NR1H3CYP1A2THRBSMN1; SMN2 | |
| SCHEMBL1271002 | 0.80 | NR1H2 (1.00) | NR1H2NR1H3 | |
| SCHEMBL1272152 | 0.79 | NR1H2 (0.86) | NR1H2NR1H3 | |
| SCHEMBL1271097 | 0.78 | NR1H2 (1.00) | NR1H2NR1H3 | |
| SCHEMBL17276731 | 0.78 | NR1H2 (0.47) | NR1H2NR1H3SMN1; SMN2HTTPIK3R2 | |
| SCHEMBL1271721 | 0.77 | NR1H2 (1.00) | NR1H2NR1H3 | |
| SCHEMBL1272163 | 0.77 | NR1H2 (0.86) | NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034526-A1 | Benzimidazole Compounds | WYETH LLC (US) | 2011-02-10 | — | — | US | disclosed |
| US-20110034526-A1 | Benzimidazole Compounds | WYETH LLC (US) | 2011-02-10 | — | — | US | disclosed |
| US-20110034526-A1 | Benzimidazole Compounds | WYETH LLC (US) | 2011-02-10 | — | — | US | disclosed |
| EP-2231617-A1 | BENZIMIDAZOLE COMPOUNDS | Wyeth LLC (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009086138-A1 | BENZIMIDAZOLE COMPOUNDS | WYETH (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009086138-A1 | BENZIMIDAZOLE COMPOUNDS | WYETH (US) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034526-A1 | Benzimidazole Compounds | NR1H4, NR1H2, NR1H3 | NR1H2 2/4885NR1H3 3/4885CYP1A2 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.